Cornelius Cilliers

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced <i>KRAS</i>^<i>G12C</i> Solid Tumors (KRYSTAL-1)

Sai‐Hong Ignatius Ou, Pasi A. Jänne, Ticiana Leal et al. · Journal of Clinical Oncology · 2022 · 287 citations · Full text

Improved Tumor Penetration and Single-Cell Targeting of Antibody–Drug Conjugates Increases Anticancer Efficacy and Host Survival

Cornelius Cilliers, Bruna Menezes, Ian Nessler et al. · Cancer Research · 2017 · 112 citations

Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy

Cornelius Cilliers, Hans Guo, Jianshan Liao et al. · The AAPS Journal · 2016 · 111 citations · Full text

Immunocytochemical Technique, Pharmacokinetic Modeling, Medicine +9

Tracking Antibody Distribution with Near-Infrared Fluorescent Dyes: Impact of Dye Structure and Degree of Labeling on Plasma Clearance

Cornelius Cilliers, Ian Nessler, Nikolas Christodolu et al. · Molecular Pharmaceutics · 2017 · 105 citations

99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation

G.J. Riely, S-H.I. Ou, Igor I. Rybkin et al. · Journal of Thoracic Oncology · 2021 · 80 citations

Medicine, Pharmacology, Pathology +7